You've offered nothing here. No DD, no insight, no facts and no knowledge. Zero. Just childish insults and accusation. Take a hike, genius.
Why don't you grow the fkkk up and stop acting like a child. You're one of the few here who actually has a brain. Use it for something better.
When Dilma took money from the State banks instead of putting new money into circulation because she wanted to limit inflation to help her re-election, she broke the law. In the past that was legal but the laws were changed. Now she wants to resign to avoid impeachment. Baloney...
It's all about cancer control. I've been saying that forever, and Cesium is ON PAR with the other isotopes. The verdict whether or not it's really better still has another 10 years of follow up.
Here is the actual conclusion of that study.
Given the general slow growth of prostate cancer and its usual chronic nature, long-term follow-up in the range of 15 years is thought necessary to definitively determine the oncological success of any treatment for clinically localised
prostate cancer. However, until any modality has this length of follow-up, short-term and intermediate-term results should be reported to ensure that newer interventions are on course to provide similar or perhaps improved cancer
control when compared with existing treatment outcomes. If any new modality for the treatment of clinically localised prostate cancer cannot be utilised until 15 years of followup is obtained, very little progress will be made in improving the treatment of this disease. Although 131Cs is the newest isotope being utilised for prostate brachytherapy, this isotope has now been in use since 2004 and it is
important to know whether with at least intermediate term follow-up 131Cs is on course to provide cancer control on par with prostate brachytherapy using the established isotopes 125I or palladium 103 (103Pd).
Patients undergoing prostate brachytherapy with 131Cs have excellent oncological outcomes at 5 years. Although more years of follow-up are required to assess the true cancer control ability of prostate brachytherapy with 131Cs,
these intermediate-term outcomes show that there is no reason at this time to suspect that 131Cs will not provide oncological outcomes AT LEAST ON PAR with those of 125I and103Pd. As follow-up of this patient cohort matures, we will
continue to publish our results to show the long-term oncological outcome of 131Cs prostate brachytherapy.
Live and learn, Amacall. I don't know everything. I did the homework and learned a lot along the way that eventually changed my sentiment. Education is a wonderful thing.
That decision is not in the hands of the patient and the best treatment may be another treatment entirely. The assumptions you make about all of this are not educated assumptions.
US market less than $100M with Europe basically zilch, and the company just bagged GliaSite. But the pumpers are screaming about a $400M market cap and a $12 PPS in the immediate future. Super Mafia is right.
Maybe you've heard or read about the global economy being under pressure, or that the brachytherapy market had a pullback? ISR is financially stable. Krachon wouldn't have accepted a job if it wasn't, but that stability is not from revenues. He'll be busy.
The lack of sales in Europe is due to Cesium being more expensive. Their health system makes them even more price sensitive than the US and his Rolodex won't help that situation much. Europe is perfectly happy with I-125. The rest of your catalysts are all speculative. Babcock was a controlling idiot. LaVoy at least has the sense to delegate.
Frothing at the mouth was my comment about the pumpers and your deleted rumor. Yeah, I know. What rumor? You evidently liked the comment enough to use as your own. I'm flattered.
For the last time, when I was a shareholder of this stock, and when Babcock was playing IR guy, I sent him a brief email on the subject you've mentioned in the interest of perhaps helping the company to expand in South America after the PR about the child in Peru. The motivation was only indirect for me as a shareholder wanting to help the company grow.
Although Dwight had responded to my few emails on other subjects, there was no response to that email and nothing more transpired. The spin that you, or someone else, started about me applying for a job had no basis in fact. No application, no rejection, no nothing. Feel free to perpetuate the spin.
We know now that Babcock had no intention of expansion, and the "feel good" Peru PR has disappeared into history with no follow up or response from the medical community. No one knows if the child survived.
Since then, the company has really done nothing, until recently, with the canning of Babcock and the hiring of some people who actually know the industry. Babcock would never had done that, ever. He wanted it all for himself, and ISR gave in to him for almost a decade. Huge mistake.
So, you and Jimmy and thourough can go on being children here and manipulate the board with silly comments and rumors. I have no financial interest. If Jimmy makes a million dollars and thourough makes a billion, they'll still be idiots. The world is full of them. GL
How about the one you're starting on the subject of some well known entity interested in ISR and an imminent 1000% price gain? Does that qualify?
Amacall, he's 45 years old. No doubt about his connections and if anyone can ramp up sales he should be the one.
There's absolutely no indication of that, either from market trends or from clinical studies. The brachy market downturn is affecting all isotope vendors and he may have had no promotional opportunity with Bard.
I've been wondering why a brachytherapy marketing director from BCR would leave a company like that? Was it actually for more opportunity with ISR, or was it because his area in BCR was suffering and he saw the writing on the wall due to the market downturn? I doubt that ISR was the one who approached him. Stay tuned...
Jimmy comes closer and closer to having a stroke from each uptick. I don't think I've ever seen anyone so obsessed with money, or with rage over not having it. His wife has to be a real ball breaker. Poor guy...
There was nothing subtle about it. If you agree with thourough's arithmetic you shouldn't be investing (neither should he if you follow his picks). You're right about the wait and see part. The easy element going forward is cleaning up the inefficiencies, ala dumping Gliasite and tightening up the sales force. Substantially growing revenues through a change in adoption is another matter. GL
Sounds like the new Marketing VP is doing his job by tidying things up. Gliasite and Cesitrex were a fail and were unnecessary overhead.